IP
IPDQF.US ImpediMed Limited
- Market cap
- USD 16.1M
- P/E
- -
- P/B
- 2.31x
- ROE
- -244.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IPDQF.US undervalued?
Graham numberThe Graham number of ImpediMed Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ImpediMed Limited fundamental analysis
No fundamental analysis for ImpediMed Limited yet.
ImpediMed Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ImpediMed Limited
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; an…
Full company profileImpediMed Limited financial statements
ImpediMed Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 5.77M | 4.80M | 4.10M | 5.69M | 8.35M | 10.5M | 11.3M | 10.1M | 12.7M | 14.6M |
| Gross Profit | 4.28M | 3.20M | 2.85M | 4.02M | 6.75M | 8.79M | -13.7M | 8.74M | 11.0M | -11.9M |
| Operating Income | -30.8M | -30.6M | -27.0M | -25.6M | -23.1M | -21.5M | -22.8M | -24.3M | -24.2M | -22.1M |
| EBITDA | -30.5M | -30.2M | -26.3M | -24.1M | -21.4M | -18.8M | -20.5M | -22.1M | -17.6M | -22.1M |
| Net Income | -27.6M | -27.2M | -24.1M | -21.4M | -20.7M | -19.9M | -20.5M | -19.8M | -23.2M | -24.9M |
| EPS | -0.07 | -0.07 | -0.06 | -0.04 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 64.3M | 41.8M | 22.6M | 33.1M | 34.2M | 58.7M | 68.7M | 47.0M | 41.7M | 34.6M |
| Total Liabilities | 5.55M | 5.77M | 6.80M | 5.70M | 8.69M | 7.66M | 7.86M | 6.24M | 21.2M | 24.4M |
| Shareholders' Equity | 58.8M | 36.0M | 15.8M | 27.4M | 25.5M | 51.0M | 60.9M | 40.7M | 20.5M | 10.2M |
| Cash & Short-term Investments | 54.9M | 31.3M | 11.3M | 19.7M | 19.7M | 40.7M | 45.7M | 24.6M | 22.2M | 15.3M |
| Total Debt | - | - | - | 871K | 474K | 170K | 1.45M | 1.14M | 14.5M | 508K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -25.6M | -23.5M | -19.6M | -19.2M | -13.3M | -15.7M | -18.0M | -17.8M | -14.6M | -20.0M |
| Capital Expenditure | 362K | 1.22M | 2.22M | 2.16M | 2.46M | 5.22M | 6.04M | 3.11M | 989K | 66.9K |
| Free Cash Flow | -25.9M | -24.7M | -21.8M | -21.4M | -2.46M | -20.9M | -24.1M | -20.9M | -15.6M | -20.1M |
| Ratios | ||||||||||
| ROE | -46.9% | -75.5% | -152.8% | -78.1% | -81.2% | -38.9% | -33.7% | -48.6% | -113.4% | -244.5% |
| ROA | -42.9% | -65.1% | -106.8% | -64.7% | -60.5% | -33.9% | -29.9% | -42.1% | -55.8% | -71.9% |
| Net Profit Margin | -478.2% | -566.5% | -588.7% | -375.4% | -247.9% | -189.4% | -180.9% | -196.9% | -182.6% | -170.4% |
| Debt to Equity | - | - | - | 0.03x | 0.02x | 0.00x | 0.02x | 0.03x | 0.71x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ImpediMed Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 580K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1027:1000 on Nov 17, 2014.
Who owns ImpediMed Limited
- Insiders 15.42%
- Institutions 21.97%
- Public & others 62.61%
- Shares outstanding 3.67B
- Free float 3.21B
ImpediMed Limited company profile
- Company name
- ImpediMed Limited
- Ticker
- IPDQF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 66
- Fiscal year end
- June
- Address
- 5900 Pasteur Court, Carlsbad, CA, United States, 92008
- Phone
- 760 585 2100
- Website
- impedimed.com
About ImpediMed Limited
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.
ImpediMed Limited management
9- Mr. Erik AndersonCEO, MD & Director
- Mr. McGregor Grant BEc, C.A., FCIS, GAICDCFO & Executive Director
- Ms. Julie KuhlkenSenior Director of Marketing
- Mr. Erik JohnsonHead of Sales
- Ms. Ashley MunozDirector of Human Resources
- Ms. Gina KimballHead of Commercial Operations
- Mr. Scott SavageChief Product Officer
- Dr. Nicole L. Stout DPTChief Clinical Innovation Officer
- Ms. Leanne Ralph AAICD, ACIS, BBusCompany Secretary